镁加铝辅助治疗反流性食管炎患者的疗效及对其生存质量的影响

CLINICAL EFFICACY OF ALMAGATE AS ADJUVANT TREATMENT IN PATIENTS WITH REFLUX ESOPHAGITIS AND ITS EFFECT ON THE QUALITY OF LIFE

目的:探讨镁加铝辅助治疗反流性食管炎(RE)患者的疗效及对其生存质量的影响。方法:选取湖北省应城市人民医院消化内科2012年2月至2014年6月收治的120例RE患者的临床资料,将患者按随机数字表法分为常规组和镁加铝组,每组各60例,常规组采用埃索美拉唑与莫沙必利治疗,镁加铝组在常规组治疗的基础上加用镁加铝辅助治疗,两组患者均连续用药2个月;观察并对比两组治疗前、后的食管内24hpH值及血清胃泌素(GAS)、血清胃动素(MOT)的变化、临床疗效和生存质量。结果:两组治疗前pH值<4的总反流时间百分比、持续反流≥5min的次数、立位时pH值<4的总时间百分比、卧位时pH值<4的总时间百分比比较,差异均无统计学意义(均P>0.05),镁加铝组治疗后上述各指标均显著低于常规组患者(均P<0.05);镁加铝组治疗后有效率(83.33%)显著高于常规组(65.00%)(P<0.05);镁加铝组治疗后GAS、MOT水平均显著高于常规组(均P<0.05);两组治疗前SF-36量表各项指标评分比较差异均无统计学意义(均P>0.05),镁加铝组治疗后的生理功能、生理职能、躯体疼痛、总体健康、活力、社会功能评分均显著高于常规组患者(均P<0.05)。结论:镁加铝辅助治疗RE患者疗效显著,并有利于改善其生存质量,值得临床推广。

Objective To investigate the efficacy of almagate combined with esomeprazole and mosaprideand its effect on the quality of life in patients with reflux esophagitis （GERD ）. Methods： 120 GERD patientsfrom February 2012 to June 2014 treated in our hospital were recruited and randomly divided into theconventional group and the almagate group, 60 cases each. Patients in the conventional group were treatedwith esomeprazole and m osapride, and those in the almagate group were treated as the conventional groupwith the addition of almagate for 2 months. The changes of the 24-hour intra-esophageal pH value and theserum gastrin （GAS） and motilin （M O T） levels before and after treatm ent as well as the clinical curativeeffect and quality of life in both groups were accessed. Results： There were no significant differences in parametersof acid reflux between two groups before treatm ent （ P 〉0. 05）. The abnormalacid reflux werenotably attenuated after treatm ent in the almagate group compared to the conventional group （ P 〈0. 05）.The response rate （83. 33% ） in the almagate group were significantly higher than those in the conventionalgroup （65% ） （ P 〈0. 05）. The serum GAS and M OT levels in the almagate group were higher than thosein the conventional group as well （ P 05）. No statistical differences were found in all items of Scale SF-36 between two groups before treatm ent （ P 〉 0 . 05） , while the physiological function, body pain, generalhealth, vitality and social function scores in the almagate group were significantly higher than those in theconventional group （ P 〈 0 . 05）. Conclusion： Almagate combined with esomeprazole and mosapride couldincrease the long-term clinical benefit and improve the quality of life in patients with GERD.